Company Description
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors.
Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021.
Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2016 |
| IPO Date | Mar 31, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 215 |
| CEO | Iraj Ali |
Contact Details
Address: 245 Hammersmith Road London, W6 8PW United Kingdom | |
| Phone | 44 20 8154 4600 |
| Website | achillestx.com |
Stock Details
| Ticker Symbol | ACHL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001830749 |
| CUSIP Number | 00449L102 |
| ISIN Number | US00449L1026 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Iraj Ali Ph.D. | Chief Executive Officer and Director |
| Dr. Sergio A. Quezada Ph.D. | Founder |
| Robert Coutts | Chief Financial Officer |
| Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Charles Swanton FMEDSCI, M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
| Lee M. Stern | Vice President of Investor Relations and External Communications |
| Daniel Carey Cazel Hood | General Counsel and Company Secretary |
| Julia Wilson | Head of Communications |
| Tariq Ahmed | Executive Vice President of People |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2025 | 15-12G | Securities registration termination |
| Mar 20, 2025 | 6-K | Report of foreign issuer |
| Mar 19, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 19, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 19, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 19, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 11, 2025 | EFFECT | Notice of Effectiveness |
| Mar 11, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 11, 2025 | 25 | Filing |
| Mar 3, 2025 | 144 | Filing |